Hiroaki Mitsuya
Hiroaki Mitsuya (born 1948) is a renowned Japanese scientist and researcher in the field of pharmacology and virology. He is best known for his significant contributions to the development of antiretroviral therapy for HIV/AIDS.
Early Life and Education[edit | edit source]
Hiroaki Mitsuya was born in Japan in 1948. He completed his medical education at the University of Tokyo, one of the most prestigious universities in Japan. After his graduation, he moved to the United States for further studies and research.
Career[edit | edit source]
Mitsuya started his career at the National Cancer Institute (NCI) in the United States. He worked under the guidance of Robert Gallo, a prominent researcher in the field of HIV/AIDS. Mitsuya's research primarily focused on the development of antiretroviral drugs to treat HIV/AIDS.
In the 1980s, Mitsuya and his team developed two groundbreaking antiretroviral drugs, Zidovudine (AZT) and Didanosine (ddI). These drugs were among the first to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS.
Mitsuya's work has had a profound impact on the treatment of HIV/AIDS. His research has not only led to the development of effective drugs but also contributed to the understanding of the disease's progression and the virus's resistance to drugs.
Recognition[edit | edit source]
Mitsuya's contributions to the field of HIV/AIDS research have been widely recognized. He has received numerous awards and honors, including the Prince Mahidol Award in Medicine and the Lasker-DeBakey Clinical Medical Research Award.
Current Work[edit | edit source]
Currently, Mitsuya continues his research at the HIV and AIDS Malignancy Branch of the NCI. His work now focuses on the development of new drugs to treat drug-resistant HIV and the exploration of new therapeutic strategies for HIV/AIDS.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
